Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Anaplastic Astrocytoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Anaplastic Astrocytoma 10
Anaplastic Astrocytoma Therapeutics under Development by Companies 12
Anaplastic Astrocytoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Anaplastic Astrocytoma Therapeutics – Products under Development by Companies 18
Anaplastic Astrocytoma Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Anaplastic Astrocytoma Therapeutics Development 21
Amgen Inc. 21
Peregrine Pharmaceuticals, Inc. 22
Tocagen Inc 23
Anaplastic Astrocytoma – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Talampanel - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Temozolomide + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Carmustine + O(6)-Benzylguanine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CPT-11 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MLN-518 + Bevacizumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Bevacizumab + Irinotecan - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 37
Avastin + AZD2171 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Therapeutic allogeneic lymphocytes + Aldesleukin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Temozolomide + Radiation Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Ritonavir + Lopinavir - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TEMODAR - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Temozolomide + Radiation Therapy - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Topotecan - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Avastin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Temozolomide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Tarceva - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Temodar + Topotecan - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Bevacizumab + Irinotecan - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Treanda - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Dendritic cells + Imiquimod - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Filgrastim + Paclitaxel + Topotecan - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Temodar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 62
Imatinib Mesylate + Temozolomide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Procarbazine + Lomustine + Vincristine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Pioglitazone hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Montanide ISA-51 + SVN53-67/M57-KLH + GM-CSF - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Erbitux - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Alloreactive Cytotoxic T Lymphocytes + Interleukin-2 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Toca 511 + Toca FC - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Autologous Tumor Lysate-Pulsed DC Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Temodal + Radiation Therapy - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AMD3100 + Avastin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
BIBF 1120 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Bevacizumab + Carboplatin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
AMG 595 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Anaplastic Astrocytoma Therapeutics – Drug Profile Updates 81
Anaplastic Astrocytoma Therapeutics – Discontinued Products 83
Anaplastic Astrocytoma Therapeutics - Dormant Products 84
Anaplastic Astrocytoma – Product Development Milestones 85
Featured News & Press Releases 85
Feb 29, 2012: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen 85
Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 85
Jan 08, 2007: Hana Biosciences Announces 2007 Corporate Goals 86
Jun 09, 2006: Hana Biosciences Receives Orphan Drug Designation For Ropidoxuridine (IPdR), For The Treatment Of Malignant Glioma 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88
List of Tables
Number of Products Under Development for Anaplastic Astrocytoma, H2 2012 10
Products under Development for Anaplastic Astrocytoma – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Amgen Inc., H2 2012 21
Peregrine Pharmaceuticals, Inc., H2 2012 22
Tocagen Inc, H2 2012 23
Assessment by Monotherapy Products, H2 2012 24
Assessment by Combination Products, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 29
Anaplastic Astrocytoma Therapeutics – Drug Profile Updates 81
Anaplastic Astrocytoma Therapeutics – Discontinued Products 83
Anaplastic Astrocytoma Therapeutics – Dormant Products 84
List of Figures
Number of Products under Development for Anaplastic Astrocytoma, H2 2012 10
Products under Development for Anaplastic Astrocytoma – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 24
Assessment by Combination Products, H2 2012 25
Assessment by Route of Administration, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Molecule Type, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 29